Mene Pangalos, Executive Vice President, Innovative Medicines & Early Development at AstraZeneca said: “We are very pleased with today’s decision by Cambridge City Council. Work is underway to prepare the site on the Cambridge Biomedical Campus and we look forward to beginning construction in the spring. Our aim is to create an open, welcoming and vibrant centre that will inspire our teams and partners to push the boundaries of scientific innovation for the benefit of patients.”
The Cambridge site will bring together AstraZeneca’s small molecule and biologics research and development activity, furthering opportunities to exploit the promise of small and large molecule combinations to make innovative medicines. It will become the company’s largest centre for oncology research, as well as housing scientists focused on cardiovascular and metabolic diseases, respiratory, inflammation and autoimmune diseases and conditions of the central nervous system. The site will also be home to a joint research centre, which will see Medical Research Council-supported researchers working side-by-side with AstraZeneca’s high throughput screening group.
In advance of the new site becoming operational at the end of 2016, over 400 AstraZeneca staff have already relocated to interim facilities in Cambridge, at the Melbourn Science Park, Cambridge Science Park and Granta Park, to cement important relationships with other members of the Cambridge life science community. This is in addition to the approximately 500 staff already located at the Company’s MedImmune facility at Granta Park.
Further detail and images of the designs for the new site are available here.
Image: Concept design of AstraZeneca Global R&D centre and corporate HQ, Cambridge, UK – illustration of proposed design, subject to planning consent © Herzog & de Meuron
_____________________________________